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SUMMARY
Objective: To determine the recurrence of bacterial vaginosis (BV) after the use of a lactic acid 
plus lactoserum liquid soap starting immediately after the treatment with oral metronidazole and 
the quality of life of the participants. Methods: A total of 123 women with diagnosis of BV with 
at least three of the following criteria: 1) homogeneous vaginal discharge without inflammation of 
the vagina or vulva; 2) vaginal pH > 4.5; 3) positive Whiff test; and 4) “clue cells” in more than 20% 
of the epithelial cells in the vagina. A Nugent score > 4 in the vaginal bacterioscopy was also used. 
After BV diagnosis, metronidazole 500  mg was administered orally bid during 7  days. Patients 
cured of BV were then instructed to use 7.5 to 10 mL of a lactic acid plus lactoserum liquid soap 
once-a-day for hygiene of the external genital region. Three subsequent control visits after starting 
the hygiene treatment (30, 60, and 90 days; ± 5 days) were scheduled. A questionnaire was applied 
in the form of visual analogue scale (VAS) in all the visits regarding: 1) level of comfort at the geni-
tal region; 2) malodorous external genitalia; 3) comfort in sexual intercourse; 4) satisfaction with 
intimate hygiene; and 5) self-esteem.  Results: Ninety two (74.8%) women initiated the use of a 
lactic acid plus lactoserum liquid soap at visit 1.  At visit 2, 3, and 4 there were 84, 62 and 42 women 
available for evaluation, respectively.  The rate of recurrence of BV was 19.0%, 24.2% and 7.1%, 
respectively in the three visits and vaginal candidiasis was observed in five treated women. Qual-
ity of life was evaluated in the 42 women who completed the four visits schedule and there were 
significant improvement in the five domains assessed.  Conclusion: A lactic acid plus lactoserum 
liquid soap for external intimate hygiene may be an option for the prevention of BV recurrence 
after treatment and cure with oral metronidazole. 
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RESUMO
Uso do ácido láctico com lactoserum em sabonete líquido íntimo 
para higiene externa na prevenção da recorrência de vaginose  
bacteriana após tratamento oral com metronidazol
Objetivo: Determinar a ocorrência de vaginose bacteriana (VB) após o uso de acido láctico com 
lactoserum em sabonete líquido iniciado imediatamente após o tratamento com metronidazol oral 
e qualidade de vida das participantes. Métodos: Um total de 123 mulheres com dianóstico de VB 
com ao menos três dos seguintes critérios: 1) leucorreia vaginal homogênea sem inflamação de 
vagina ou vulva; 2) pH vaginal > 4,5; 3) teste positivo de Whiff; e 4) “clue cells” em mais de 20% das 
células epiteliais na vagina. O escore de Nugent > 4 na bacterioscopia vaginal também foi usado. 
Após o diagnóstico de VB, metronidazol 500 mg oral foi ministrado durante 7 dias. Pacientes cura-
dos da VB foram instruídos a usar 7,5 a 10 mL de acido láctico com lactoserum em sabonete líqui-
do uma vez ao dia para higiene da genitália externa. Três visitas de controle foram agendadas (30, 
60 e 90 dias; ± 5 dias). Um questionário foi aplicado na forma de escala visual análoga (EVA) em 
todas as visitas sobre: 1) nível de conforto na região genital; 2) mau odor na genitália; 3) conforto 
na relação sexual; 4) satisfação com higiene íntima; e 5) autoestima. Resultados: Noventa e duas 
(74,8%) mulheres iniciaram o uso de ácido láctico com lactoserum líquido na visita 1. Na visita 2, 
3 e 4 foram 84, 62 e 42 mulheres para avaliação, respectivamente. A taxa de recorrência da VB foi 
19,0%, 24,2% e 7,1%, respectivamente nas três visitas e candidíase vaginal foi observada em cinco 
mulheres. Qualidade de vida foi avaliada em 42 mulheres que completaram as quatro visitas agen-
dadas e houve uma melhora significativa nos cinco domínios avaliados. Conclusão: O uso de acido 
láctico com lactoserum em sabonete líquido para higiene externa intima pode ser uma opção para 
a prevenção da recorrência de VB após tratamento e cura com metronidazol oral. 
Unitermos: Vaginose bacteriana; metronidazol; resultado de tratamento.
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INTRODUCTION
Bacterial vaginosis (BV) is the most common vagi-
nitis among women of reproductive age.  It affects 15-
25% of patients with gynecological complaints and has 
a prevalence rate of 60% in women attended in sexual 
transmitted diseases (STDs) clinics1-3.  BV is defined as 
a condition characterized by the replacement of the nor-
mal vaginal flora in which lactobacilli are predominant 
by proliferating anaerobic bacteria including Gardnerella 
vaginalis (GV).
Metronidazole, administered by oral or vaginal route, 
is the drug of choice recommended for the treatment of 
BV by the US Center for Disease Controls (CDC)4.  Treat-
ment with metronidazol is associated with up to 80% re-
mission after 7-10 days administration either through oral 
or vaginal route5. However, therapeutic failures and BV 
recurrence are observed in 30% and 70% of patients one 
month and three months after treatment, respectively6,7.  
Failure to restore the normal vaginal flora is consid-
ered the main reason for BV recurrence after treatment 
with metronidazole. For this reason, acidification of the 
vaginal environment has been proposed as BV treatment, 
or as an alternative for recurrence prevention1,3.  It has 
also been suggested that a vaginal pH higher than the 
physiological range (3.8 to 4.5) induces the growth and 
predominance of anaerobic bacteria which is the case of 
most patients diagnosed with BV8. In general, these bac-
teria are unable to grow at pH below 4.59.  
In one study with patients diagnosed with BV it was 
observed that lactobacilli were predominant in the con-
trol group whereas anaerobes were predominant in BV 
patients10. The use of intravaginal lactate-gel (pH  3.5; 
5 mL) for 7 days was as effective as oral metronidazole 
(500  mg bid for 7  days). However, although anaerobes 
were significantly reduced, BV was not reduced. 
A lactic acid plus lactoserum liquid soap (Dermacyd® 
Femina, Sanofi-aventis, Brazil) is available on the market 
as an acid liquid soap with lactic acid plus lactoserum 
with a pH ~ 4.0 and is indicated for helping in the pre-
vention of gynecological infections when used for exter-
nal genitalia hygiene.  The formulation contains a lactic 
acid plus lactoserum complex and could contribute to 
maintain a physiologic vulvovaginal pH although there 
is no evidence to that effect, neither that it prevents BV 
recurrence. 
This study was designed to determine the recurrence 
rate of BV up to three months after treatment with a lac-
tic acid plus lactoserum liquid soap. The treatment was 
started immediately after BV remission obtained with the 
standard treatment with oral metronidazole. The study 
objective was also to evaluate the rate of vulvovaginal 
candidiasis throughout the period of external hygiene 
procedure with a lactic acid plus lactoserum liquid soap 
as well as the patients’ quality of life. 
METHODS
This open label non-comparative study was conducted at 
the Human Reproduction Unit, Department of Obstetrics 
and Gynecology, Universidade de Campinas (UNICAMP), 
Medical School, Campinas, Brazil. The project was ap-
proved by the Institutional Ethics Committee and all 
volunteers signed an informed consent prior to study in-
clusion.  The study was conducted from September 2007 
through December 2008. This study has been sponsored 
by Sanofi-aventis Brazil. The investigators were respon-
sible for the study design and conduction, data manage-
ment and statistical analysis, as well as for the manuscript 
preparation, with no interference from the sponsor.
SUBJECTS
Women were enrolled if they fulfilled the inclusion crite-
ria as follows: age < 50 years; clinically confirmed diagno-
sis of BV; vaginal fresh exam and Gram stain test negative 
for candidiasis and Trichomonas vaginalis.  The exclusion 
criteria were: women with previous or current oral met-
ronidazole therapeutic failure for BV, genital herpes le-
sions or warts, pregnant women or those breastfeeding in 
the last three months prior to enrollment, history of any 
STDs in the last six months before enrollment, includ-
ing human immunodeficiency virus infection, diabetes 
mellitus or other chronic disease, use of corticosteroids, 
chemotherapy, alcohol or drug abuse. 
DIAGNOSIS OF BV
The diagnostic tests included vaginal pH measurement, 
Whiff test and the collection of three vaginal swabs: one 
to perform a fresh exam with saline solution; one for a 
fresh exam with KOH and the third to perform a Gram-
stained bacterioscopy. The clinical diagnosis of BV was 
defined according to at least three of the following crite-
ria: 1) homogeneous vaginal discharge without inflam-
mation of the vagina or vulva; 2) vaginal pH  >  4.5; 3) 
positive Whiff test; and 4) “clue cells” in more than 20% 
of the epithelial cells in a fresh vaginal exam. Nugent 
score > 4 in the Gram-stained vaginal bacterioscopy was 
also used11-13.
TREATMENTS
After BV was diagnosed, oral metronidazole 500 mg was 
administered bid during seven days.  Furthermore, all BV 
remission-patients were instructed to proceed with geni-
tal hygiene consisting of a once-a-day topical rubbing of 
a small quantity (between 7.5 to 10 mL) of a lactic acid 
plus lactoserum liquid soap, till foam is produced. Rins-
ing with abundant tap water was required after product 
administration.  All subjects were instructed to avoid the 
use of genital deodorants, spermicides, female or male 
condoms, diaphragm, and tampons during the study. 
Compliance was checked trough clinical diaries.  
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EVALUATION PERIOD
Each participant performed five visits: Visit 0 (admission) 
to confirm the BV diagnosis and to provide treatment with 
oral metronidazole; Visit 1 to confirm remission of BV and 
to initiate the use of a lactic acid plus lactoserum liquid 
soap (between day 8 and 12 after the end of the treatment 
with metronidazole). During visit 1 the cure of BV was 
evaluated with the same criteria used at the admission visit 
and remission was considered only if both clinical criteria 
and Nugent criteria were met. Three additional control vi-
sits (Visit 2, 3 and 4 at 30, 60 and 90 days ± 5, respectively) 
were scheduled after starting treatment with the soap. 
Patients in whom BV remission was diagnosed were in-
structed to use a lactic acid plus lactoserum liquid soap for 
external intimate hygiene. In addition, vaginal content 
for the diagnosis of candidiasis was collected as well as 
vaginal pH.  Women with no disease remission at this 
visit were excluded from the study.  During the visits 2, 
3, and 4 the same procedures performed in visit 1 were 
carried out. 
SELF-EVALUATION QUESTIONNAIRE
A self-evaluation questionnaire was developed for this 
study and it was applied in the form of visual analogue 
scale (VAS) in visits 1, 2, 3, and 4 after enrollment.  The 
VAS scale is an instrument in which 0 (zero) represents 
that the subject was unsatisfied with the treatment and 10 
fully satisfied. Applied questions were, as follows: 1) level 
of comfort in the genital region; 2) malodorous external 
genitalia; 3) comfort in sexual intercourse; 4) satisfaction 
or not regarding intimate hygiene; and 5) self-esteem. 
STATISTICAL ANALYSIS
The sample size was established according to a 95% con-
fidence interval (CI) of BV recurrence with an accuracy 
of 10%. A 40% BV recurrence rate was assumed and the 
number of subjects was set at 91. Assuming 33% lost-to-
follow-up (LFU), we estimated a total enrollment of 122 
women. The primary dependent efficacy variable was the 
rate of BV recurrence (laboratory diagnosis) measured 
during the three months of topical (genital region) hygiene 
with a lactic acid plus lactoserum liquid soap.  The second-
ary dependent variable was the rate of vulvovaginal can-
didiasis measured during the three months of a lactic acid 
plus lactoserum liquid soap. Treatment was considered 
successful in case of no BV recurrence assessed during the 
three months follow up period. 
The results of the five-question VAS self-applied ques-
tionnaire were presented as mean, median, range, and 
standard deviation (SD).  The analysis included a paired 
t-test to compare values before and after treatment. The 
analysis of all the data follows the principle of intention to 
treat and data was presented as mean ± SD and the level of 
significance was established at p < 0.05.
RESULTS
A total of 133 women were included in the study. Mean 
age was 32.0 ± 7.2, ranging from 18 to 50 year ; 67 women 
(54.5%) were white; 31 (25.2%) were black and 25 sub-
jects (20.3%) biracial.  Body mass index (BMI; kg/m2) was 
26.5 ± 5.4 with a range of 16.8 to 41.  Contraceptive prac-
tices at baseline were reported by the patients as follows: 82 
(66.7%) were users of the copper intrauterine device (IUD, 
62.6%) or of a levonorgestrel-releasing intrauterine system 
(LNG-IUS; 4.1%), 12 (9.8%) were users of male condom, 
19 (15.4%) of combined oral (8.1%) or injectable contra-
ceptives (7.3%), and the other had undergone male or fe-
male sterilization.  Only 13 (10.6%) volunteers presented 
some clinical condition and the three most prevalent were 
blood hypertension, bronchitis and epilepsy. 
At visit 0 (baseline) 123 patients were enrolled, 117 
(95.1%) presented vaginal discharge at the gynecological 
exam; vaginal pH > 4.5 was observed in 121 (98.4%) of 
the patients, “clue cells” at the fresh exam in all the 123 
patients, positive Whiff test in 119 (96.8%) of the sub-
jects, and Nugent score >  4 in all the patients. Conse-
quently, all the patients fulfilled at least three of the BV 
criteria for enrollment and all of them were instructed to 
initiate the oral metronidazole treatment.  
At visit 1, after the end of the treatment with metroni-
dazole, 100 (81.3%) patients showed negative BV, 9 pre-
sented no remission and the other 14 were not evaluated 
due to LFU (12 women), one due to protocol violation, 
and the other because she did not wish to continue in the 
study.  However, only 92 women initiated the treatment 
because 5 were LFU, two presented candidiasis and one 
experienced an adverse event.    
At visit 2, 30 days after initiation of a lactic acid plus 
lactoserum liquid soap, 84 patients were available for 
evaluation because five women were discontinued due 
to candidiasis, two were discontinued due to protocol 
violation and one de to lost to follow-up. At visit 3, 60 
days after initiation of a lactic acid plus lactoserum liq-
uid soap, 62 patients were available for evaluation. The 
other 22 women were discontinued due to recurrence of 
BV (16), LFU (3), candidiasis (2), and one due to proto-
col violation.  At visit 4, 90 days after the initiation of a 
lactic acid plus lactoserum liquid soap use, 42 patients 
were available for evaluation. The other 20 women were 
discontinued due to recurrence of BV (15), candidiasis 
(3), one due to LFU, and one due to protocol violation. 
Figure 1 shows the follow-up flowchart of the patients in 
the study.  The rate of BV recurrence was 19.0, 24.2 and 
7.1%, respectively in the three visits (Table 1).
There were 11 adverse events associated with the use of 
the product under investigation in 9 women (9.8%); vagi-
nal candidiasis which occurred in 5 women (5.4%) dur-
ing the study treatment was the most common. The others 
were vulvar erithema, hyperemia, irritation and itching.
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Regarding the evaluation of quality of life the data 
are shown in Table 2. We only compared 42 women who 
completed the four visits scheduled for the entire study. 
Comparison between visit 1 (after remission with the use 
of metronidazol) and the last visit (visit 4) showed that 
among the 5 domains assessed all variables showed signifi-
cant improvement at the end of the treatment.  
DISCUSSION
Oral or vaginal administration of metronidazol is the 
current, first-line and accepted treatment for BV4,5.  Nev-
ertheless, the high rate of remission is usually followed 
by high and unacceptable rates of recurrence6,7,14,15 even 
when metronidazol was prescribed at higher doses16. Al-
beit the natural history of BV was almost totally eluci-
dated, complications such as pelvic inflammatory disease 
(PID), premature membrane rupture, premature birth, 
endometritis, and increased susceptibility to reproduc-
tive tract infections (RTIs) including HIV are the main 
concerns with BV17,18.  In addition, the quality of life of 
women with BV, mainly those with recurrent BV, is ham-
pered in many domains and in severely affected women it 
can lead to depression and adversely impact relationships; 
however, literature regarding quality of life of women with 
BV is scarce18.  
The quality of life evaluated at the end of the treat-
ment showed significant improvement in the five do-
mains assessed.  It is important to note that the level of 
comfort, the improvement in malodorous external geni-
talia, the comfort in sexual intercourse and the satisfac-
tion with intimate hygiene were issues that could con-
tribute to self-esteem which was also enhanced.  In an 
Italian survey19,20, women and physicians reported that a 
more acid vaginal pH was associated to a more satisfac-
tory sexual activity, more healthy genital conditions and 
considered that vaginal pH was an important aspect of 
everyday life. In general, the study’s findings showed that 
appropriate intimate hygiene can be an important tool in 
women’s everyday life.  Our results were in accordance 
with these findings and the treatment can contribute to 
women’s quality of life.  
Our results showed that the use of a lactic acid plus 
lactoserum liquid soap, after laboratory confirmed BV 
remission, using the standard oral metronidazol treat-
ment, was a good option to avoid BV recurrence.  If we 
take into account that almost 70% of the cases of recur-
rence are reported up to 90 days after treatment with 
metronidazole6,7, our cumulative data of 50% recurrence 
with the use of a lactic acid plus lactoserum liquid soap 
confirm that this is a good option.  
Recurrence of BV is a common problem in gyneco-
logical visits6,7 and a main concern for both patients and 
physicians. In a previous study12 with women with con-
firmed diagnosis and symptomatic BV, the recurrence 
Visit 1: 8-12 days after metronidazole
Enrolled: 123
Negative results for BV: 100
No cure: 9
LFU*: 12
Protocol violation: 1
Removal of consent: 1
Visit 0: admission
Visit 2: 30 days
Evaluated: 62
Negative results for BV: 47
Visit 3: 60 days
Evaluated: 42
Negative results for BV: 39
Recurrence of BV: 15
LFU*: 1
Candidiasis: 3
Protocol violation: 1
Visit 4: 90 days
Evaluated: 84
Negative results for BV: 68
Candidiasis: 5
Protocol violation: 2
LFU*: 1
Recurrence of BV: 16
LFU*: 3
Candidiasis: 2
Protocol violation: 1
Initiated a lactic acid plus lactoserum liquid soap: 92
Candidiasis: 2
LFU*: 5
Adverse event: 1
Visit n Yes 95% CI
V2 84 16 (19.0%) 10.6-27.4
V3 62 15 (24.2%) 13.9-35.3
V4 42 3 (7.1%) 0.0-15.1
Ever 84 34 (40.5%) 30.0-51.0
CI, confidence interval.
Table 1 – Recurrence of bacterial vaginosis throughout the 
study
Figure 1 – Follow-up flowchart of the patients in the study.
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of BV was 69% after remission with standard oral met-
ronidazol through 12 months of follow-up.  One of 
the strength of that study was a 94% follow-up with at 
least one control. The identified variables associated to 
recurrence were past history of BV, regular sex partner 
throughout the study and female sex partners14. The main 
confounding variable was the fact that a regular partner 
was associated to recurrence of BV when a previous 
study showed that new partners are a risk factor for re-
currence18.
One of the problems with BV is that there are no clear 
recommendations to avoid or to treat recurrence and it 
was stated that 500  mg of oral metronidazole bid for 7 
days should be the first option due to the high remission 
rates19, albeit CDC20 and UK guidelines21 do not report 
evidence of such treatment results. In addition, treatment 
with metronidazole gel or placebo did not show benefits 
of the drug in the 28-week follow-up22.  
Moreover, it was observed that secondary vaginal 
candidiasis occurred significantly more often in the 
group of women treated with metronidazole22; however, 
although vaginal candidiasis was the most common side-
effect observed in our study it only accounted for almost 
6% of the patients treated with a lactic acid plus lactose-
rum liquid soap.  
Although vaginal acidification has recently been stud-
ied, the results have been disappointing and the use of 
acetic acid gel was ineffective in the treatment of BV23,24. 
However, recently, in a Philippine study25, a product sim-
ilar to the experimental one in this study was used.  This 
was a three arm-study; one with metronidazole; one with 
lactic acid gel in an intravaginal administration and the 
other arm with a combination of both drugs.  The admin-
istration of intravaginal lactic gel offered better results 
than the other two treatments regarding the growth of 
lactobacilli colonies, and metronidazole with lactic acid 
gel caused a significant reduction of malodorous vaginal 
discharge (Whiff test) and the lowest recurrence of BV.  
Nevertheless, the significant decrease in the pH level 
and frequency of “clue cell” positive patients was not sig-
nificantly different between the three treatment groups. 
In addition, the main limitation of that study was that the 
follow-up period was only up to 56 days and the partici-
pants were not individualized as remission or persistence 
of BV25.  In addition, we need to take into account that it 
was established26 that the possibility of changing Nugent 
score every 6 or 12 months was normally distributed. 
Our study showed that the use of a lactic acid plus lac-
toserum liquid soap, after standard treatment with met-
ronidazole for BV was able to control the recurrence of 
the infection and this had an impact on the improvement 
of quality of life, a neglected aspect of BV women’s life. 
One criticism could be that almost 67% of the women 
assessed were users of a copper IUD or an LNG-IUS and 
it was described that among new users of IUD the preva-
lence of BV was 19.7%27.  Nevertheless, our own previous 
results25 showed that BV after one month of IUD inser-
tion was not associated with IUD complications, with the 
exception of dysmenorrhea, and there are no reports that 
users of IUD are more prone to recurrence of BV after ap-
propriate treatment.  However, our study has some limi-
tations indeed. The study was non-blinded, we did not 
deploy an untreated control group which could provide 
more accurate information about the treatment group 
and the follow-up was only up to 90 days after beginning 
the treatment. Consequently, we cannot anticipate what 
the results will be in the long-term follow-up. 
Although further studies are required in order to rec-
ommend the use of a lactic acid plus lactoserum liquid soap 
as a treatment against BV recurrence, our results showed 
that the use of a lactic acid plus lactoserum liquid soap is a 
good option for the prevention of BV recurrence after treat-
ment and cure with metronidazole, specially if we take into 
account the lack of other positive treatments for BV recur-
rence and considering that intimate hygiene was described 
as a tool for BV treatment or prevention28.  The prevention 
of BV recurrence probably requires several treatment mo-
dalities and the findings of our study can help women with 
BV and could help in the reduction of BV associated com-
plications as well as improve quality of life. 
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 Table 2 –  Different domains of quality of life at the different visits 
Domain Visit 2 (n = 42) Visit 5 (n = 42) p-value
Level of comfort 8.1 ± 1.9 (3.0-10.0) 9. 2 ± 1.1 (5.8-10.0) < 0.0001
Malodorous external genitalia 8.5 ± 1.9 (3.5-10.0) 9.4 ± 1.1 (4.0-10.0) 0.0027
Comfort in sexual intercourse 8.1 ± 2.4 (0.5-10.0) 9.3 ± 0.8 (7.2-10.0) = 0.0003
Satisfied with the intimate hygiene 8.4 ± 2.1 (1.5-10.0) 9.3 ± 1.3 (2.6-10.0) = 0.0003
Self-esteem 8.5 ± 1.9 (1.0-10.0) 9.4 ± 0.7 (6.8-10.0) < 0.0015
Sum of the scores 41.4 ± 7.5 (25.7-50.0) 46.6 ± 3.9 (29.8-50.0) < 0.0001
All values are mean ± SD (range); *LFU, lost-to-follow-up.
M. VALERIA BAHAMONDES ET AL.
420 Rev Assoc Med Bras 2011; 57(4):415-420
REFERENCES
1. Hillier S, Holmes KK. Bacterial vaginosis. In: Holmes KK, Mardh 
PA, Sparling PF, Lemon SM, Stamm WE, Piot P et al., editors. Sexu-
ally transmitted diseases. 3rd ed. New York: McGraw-Hill; 1999. 
p.563-86.
2. Spiegel CA. Gardnerella vaginalis and Mobiluncus Species. In: Man-
dell GL, Bennett JE, Dolin R, editors. Principles and practice of in-
fectious diseases. 5th Philadelphia: Churchill Livingstone; 2000. v.2, 
p. 2383-6.
3. Martin HL, Richardson BA, Nyange PM, Lavreys L, Hiller SL, Cho-
han B et al. Vaginal lactobacilli, microbial flora, and risk of human 
immunodeficiency virus type 1 and sexually transmitted disease ac-
quisition. J Infect Dis 1999;180:1863-8.
4. Centers for Disease Control and Prevention. 1998 Guidelines for 
treatment of sexually transmitted diseases. MMWR Morb Mortal 
Wkly Rep 1998;47(RR-1):70-9.
5. Livengood CH, Soper DE, Sheehan KL, Fenner DE, Martens MG, 
Nelson AL et al. Comparison of once-daily and twice-daily dosing of 
0.75% metronidazole gel in the treatment of bacterial vaginosis. Sex 
Transm Dis 1999;26:137-42.
6. Sobel JD, Schmitt C, Meriwether C. Long-term follow-up of patients 
with bacterial vaginosis treated with oral metronidazole and topical 
clindamycin. J Infect Dis 1993;167:783-4.
7. Boris J, Pahlson C, Larsson PG. Six years observation after suc-
cessful treatment of bacterial vaginosis. Infect Dis Obstet Gynecol 
1997;5:297-302. 
8. Ferris DG, Francis SL, Dickman ED, Miler-Miles K, Waller JL, Mc-
Clendon N. Variability of vaginal pH determination by patients and 
clinicians. J Am Board Fam Med 2006;19:368-73. 
9. Soper DE. Gynecologic complications of bacterial vaginosis: fact or 
fiction? Curr Infect Dis Rep 1999;1:393-7.  
10. Andersch B, Forssman L, Lincoln K, Torstensson P. Treatment 
of bacterial vaginosis with an acid cream: a comparison between 
the effect of lactate-gel and metronidazole. Gynecol Obstet Invest 
1986;21:19-25.
11. Simoes JA, Discacciati MG, Brolazo EM, Portugal PM, Dini DV, 
Dantas MC. Clinical diagnosis of bacterial vaginosis. Int J Gynaecol 
Obstet 2006;94:28-32. 
12. Amsel R, Totten PA, Spiegel CA, Chen KCS, Eschenbach D, Holmes 
KK. Non-specific vaginitis. Diagnostic criteria and microbial and 
epidemiological associations. Am J Med 1983;74:14-22.
13. Nugent RP, Krohn MA, Hillier SL. Reliability of diagnosing bacterial 
vaginosis is improved by a standardized method of gram stain inter-
pretation. J Clin Microbiol 1991;29:297-301.
14. Bradshaw CS, Morton AN, Hocking J, Garland SM, Morris MB, 
Moss LM et al. High recurrence rates of bacterial vaginosis over the 
course of 12 months after oral metronidazole therapy and factors as-
sociated with recurrence. J Infect Dis 2006;193:1478-86.
15. Bradshaw CS, Tabrizi SN, Fairley CK, Morton AN, Rudland E, Gar-
land SM. The association of Atopobium vaginae and Gardnerella 
vaginalis with bacterial vaginosis and recurrence after oral metroni-
dazole therapy. J Infect Dis 2006;194:828-36.
16. Gray RH, Wabwire-Mangen F, Kigozi G, Serwadda D, Moulton LH, 
Quinn TC et al. Randomized trial of presumptive sexually transmit-
ted disease therapy during pregnancy in Rakai, Uganda. Am J Obstet 
Gynecol 2001;185:1209-17.
17. Camargo RP, Simões JA, Cecatti JG, Alves VM, Faro S. Impact of 
treatment for bacterial vaginosis on prematurity among Brazilian 
pregnant women: a retrospective cohort study. São Paulo Med J 
2005;123:108-12. 
18. Hay P. Recurrent bacterial vaginosis. Curr Opin Infect Dis 2009; 
22:82-6.
19. Alfonsi GA, Shlay JC, Parker S, Neher JO. What is the best ap-
proach for managing recurrent bacterial vaginosis? J Fam Pract 
2004;53:650-2.
20. CDC Sexually Transmitted Disease Treatment Guidelines 2006. 
MMWR Morb Mortal Wkly Rep 2006;55:50-2. 
21. Clinical Effectiveness Group British Association for Sexual Health 
and HIV. National Guideline for the Management of Bacterial Vagi-
nosis; 2006. [cited 2009 oct. 22. Available from:http://www.guide-
line.gov. 
22. Sobel JD, Ferris D, Schwebke J, Nyirjesy P, Wiesenfeld HC, Peipert 
J et al. Suppressive antibacterial therapy with 0.75% metronidazole 
vaginal gel to prevent recurrent bacterial vaginosis. Am J Obstet Gy-
necol 2006;194:1283-9.
23. Holley RL, Richter HE, Varner RE, Pair L, Schwebke JR. A random-
ized, double-blind clinical trial of vaginal acidification versus place-
bo for the treatment of symptomatic bacterial vaginosis. Sex Transm 
Dis 2004;31:236-8. 
24. Boeke AJ, Dekker JH, van Eijk JT, Kostense PJ, Bezemer PD. Effect of 
lactic acid suppositories compared with oral metronidazole and pla-
cebo in bacterial vaginosis: a randomized clinical trial. Genitourin 
Med 1993;69:388-92.
25. Decena DCD, Co JT, Manalastas RM, Palaypayon EP, Padolina CS, 
Sison JM et al. Metronidazole with Lactacyd vaginal gel in bacterial 
vaginosis. J Obstet Gynaecol Res 2006;32:243-51.
26. Ness RB, Kip KE, Soper DE, Stamm CA, Rice P, Richter HE. Variabil-
ity of bacterial vaginosis over 6 to 12-month intervals. Sex Transm 
Dis 2006;33:381-5.
27. Ferraz do Lago R, Simões JA, Bahamondes L, Camargo RP, Perrotti 
M, Monteiro I. Follow-up of users of intrauterine device with and 
without bacterial vaginosis and other cervicovaginal infections. 
Contraception 2003;68:105-9.
28. Guaschino S, Benvenuti C; SOPHY Study Group. SOPHY project: 
an observational study of vaginal pH, lifestyle and correct intimate 
hygiene in women of different ages and in different physiopathologi-
cal conditions. Part II. Minerva Ginecol 2008;60:353-62. 
